【导读】百花医药或易主，自12月29日开市起停牌 中国基金报记者 闻言 12月26日晚间，百花医药发布公告称，公司控股股东、实际控制人米在齐、米恩华、杨小玲正在筹划公司股份协议转让事宜，可能导致公司控制权发生变 更。 百花医药计划自12月29日开市起停牌，预计停牌时间不超过2个交易日。12月26日收盘，百花医药股价报12.24元/股，涨幅达5.88%，总市值为47.07亿元。 筹划股份转让前解除一致行动关系 公告显示，2025年12月1日，米在齐、米恩华、杨小玲及其一致行动人李建城确认不再续签《一致行动人协议书》，一致行动关系自动解除。 2024年12月2日，米在齐、米恩华、杨小玲及其一致行动人李建城签署《一致行动人协议书》，有效期一年，合计持有百花医药24.58%的股份。 如今，米在齐、米恩华、杨小玲仍为百花医药控股股东、实际控制人，李建城不再是百花医药控股股东、实际控制人之一致行动人，其所持百花医药股份 不再合并计算。 具体来看，米在齐、米恩华、杨小玲直接持有百花医药股份的比例分别为8.99%、6.70%、4.99%。 | 姓名/名称 | 持股数量(股) | 持股比例 | | --- | --- | -- ...

Core Viewpoint - Baihua Pharmaceutical is planning a share transfer that may lead to a change in control of the company, with a trading suspension expected to last no more than two trading days starting December 29 [1]. Group 1: Shareholding Structure - The controlling shareholders, Mi Zaiqi, Mi Enhua, and Yang Xiaoling, are in the process of transferring shares, which may alter the company's control [1]. - As of December 1, 2025, the agreement among Mi Zaiqi, Mi Enhua, Yang Xiaoling, and their former joint action partner Li Jiancheng has been terminated, resulting in a change in the calculation of shareholding percentages [3]. - Mi Zaiqi, Mi Enhua, and Yang Xiaoling collectively hold 20.68% of Baihua Pharmaceutical, with individual holdings of 8.99%, 6.70%, and 4.99% respectively [4]. Group 2: Financial Performance - Baihua Pharmaceutical has experienced significant fluctuations in net profit from 2019 to 2024, with figures of 34.38 million, -320 million, 59.83 million, -34.76 million, 12.97 million, and 41.48 million yuan respectively [4]. - In the first three quarters of 2025, the net profit attributable to shareholders increased by 36.41% year-on-year, driven by improved project management and cost control [6]. - The company's total revenue for the current reporting period is approximately 965.20 million yuan, reflecting a year-on-year increase of 2.32% [6].